Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Executive Summary

Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.

Advertisement

Related Content

FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed
FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Pending Biosimilars
Biosimilars Program Could 'Explode,' Woodcock Warns Congress
Biosimilar Market Formation Isn't Going According To Plan
Surge In Applications Triggers User Fee Inflation

Topics

Advertisement
UsernamePublicRestriction

Register

PS118854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel